ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
Summary
**media[1023511]** Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting
Description
**media[1023511]** Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source